Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte™ for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track

Reuters

10/07

Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte™ for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track

Soligenix Inc. has announced progress in its confirmatory Phase 3 clinical trial of HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). The company reported that the first Data Monitoring Committee meeting found no safety concerns, confirming an acceptable safety profile consistent with previous studies. Patient enrollment for the FLASH2 study is proceeding as planned, with an enrollment update expected in the fourth quarter of 2025. A pre-specified blinded interim efficacy analysis is targeted for the first half of 2026, and topline results are anticipated in the second half of 2026. No efficacy results from this ongoing study have been presented yet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH91092) on October 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2573954227"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573954227\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573954227?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573954227","market":"us","top_or_hot":-1,"title":"Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte™ for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte™ for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Soligenix Inc. has announced progress in its confirmatory Phase 3 clinical trial of HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). The company reported that the first Data Monitoring Committee meeting found no safety concerns, confirming an acceptable safety profile consistent with previous studies. Patient enrollment for the FLASH2 study is proceeding as planned, with an enrollment update expected in the fourth quarter of 2025. A pre-specified blinded interim efficacy analysis is targeted for the first half of 2026, and topline results are anticipated in the second half of 2026. No efficacy results from this ongoing study have been presented yet.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH91092) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte™ for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte™ for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-07 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte™ for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Soligenix Inc. has announced progress in its confirmatory Phase 3 clinical trial of HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). The company reported that the first Data Monitoring Committee meeting found no safety concerns, confirming an acceptable safety profile consistent with previous studies. Patient enrollment for the FLASH2 study is proceeding as planned, with an enrollment update expected in the fourth quarter of 2025. A pre-specified blinded interim efficacy analysis is targeted for the first half of 2026, and topline results are anticipated in the second half of 2026. No efficacy results from this ongoing study have been presented yet.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH91092) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNGX","symbol_name":"Soligenix, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL2lm7Lh:1","article_id":"2573954227","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573954227","pubTimestamp":1759836645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track. Soligenix Inc. has announced progress in its confirmatory Phase 3 clinical trial of HyBryte  for the treatment of cutaneous T-cell lymphoma . The company reported that the first Data Monitoring Committee meeting found no safety concerns, confirming an acceptable safety profile consistent with previous studies. Patient enrollment for the FLASH2 study is proceeding as planned, with an enrollment update expected in the fourth quarter of 2025. A pre-specified blinded interim efficacy analysis is targeted for the first half of 2026, and topline results are anticipated in the second half of 2026. No efficacy results from this ongoing study have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNGX":"Soligenix, Inc.","BK4139":"生物科技"},"translate_title":"Soligenix宣布Hybryte 3期FLASH2试验取得关键安全里程碑™用于皮肤T细胞淋巴瘤；招生进度步入正轨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNGX":0.9},"content_text":"Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte™ for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track\n    \n\n        Soligenix Inc. has announced progress in its confirmatory Phase 3 clinical trial of HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). The company reported that the first Data Monitoring Committee meeting found no safety concerns, confirming an acceptable safety profile consistent with previous studies. Patient enrollment for the FLASH2 study is proceeding as planned, with an enrollment update expected in the fourth quarter of 2025. A pre-specified blinded interim efficacy analysis is targeted for the first half of 2026, and topline results are anticipated in the second half of 2026. No efficacy results from this ongoing study have been presented yet.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH91092) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}